1. Home
  2. SBFM vs CPHI Comparison

SBFM vs CPHI Comparison

Compare SBFM & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SBFM
  • CPHI
  • Stock Information
  • Founded
  • SBFM 2006
  • CPHI N/A
  • Country
  • SBFM United States
  • CPHI China
  • Employees
  • SBFM N/A
  • CPHI N/A
  • Industry
  • SBFM Biotechnology: Pharmaceutical Preparations
  • CPHI Biotechnology: Pharmaceutical Preparations
  • Sector
  • SBFM Health Care
  • CPHI Health Care
  • Exchange
  • SBFM Nasdaq
  • CPHI Nasdaq
  • Market Cap
  • SBFM 3.7M
  • CPHI 4.2M
  • IPO Year
  • SBFM N/A
  • CPHI N/A
  • Fundamental
  • Price
  • SBFM $2.75
  • CPHI $0.18
  • Analyst Decision
  • SBFM Strong Buy
  • CPHI
  • Analyst Count
  • SBFM 1
  • CPHI 0
  • Target Price
  • SBFM $15.00
  • CPHI N/A
  • AVG Volume (30 Days)
  • SBFM 1.8M
  • CPHI 307.1K
  • Earning Date
  • SBFM 11-05-2024
  • CPHI 11-13-2024
  • Dividend Yield
  • SBFM N/A
  • CPHI N/A
  • EPS Growth
  • SBFM N/A
  • CPHI N/A
  • EPS
  • SBFM N/A
  • CPHI N/A
  • Revenue
  • SBFM $32,959,491.00
  • CPHI $5,544,620.00
  • Revenue This Year
  • SBFM $86.70
  • CPHI N/A
  • Revenue Next Year
  • SBFM $126.76
  • CPHI N/A
  • P/E Ratio
  • SBFM N/A
  • CPHI N/A
  • Revenue Growth
  • SBFM 61.94
  • CPHI N/A
  • 52 Week Low
  • SBFM $2.11
  • CPHI $0.13
  • 52 Week High
  • SBFM $608.00
  • CPHI $0.70
  • Technical
  • Relative Strength Index (RSI)
  • SBFM 47.83
  • CPHI 46.97
  • Support Level
  • SBFM $2.51
  • CPHI $0.13
  • Resistance Level
  • SBFM $2.82
  • CPHI $0.20
  • Average True Range (ATR)
  • SBFM 0.29
  • CPHI 0.02
  • MACD
  • SBFM -0.02
  • CPHI 0.00
  • Stochastic Oscillator
  • SBFM 22.34
  • CPHI 80.38

About SBFM Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.

Share on Social Networks: